Factors Associated With Patients Not Receiving Oral Anticancer Drugs

Key Points Question How many patients with cancer do not receive oral anticancer drug prescriptions, and what are the factors associated with this failure to receive these drugs? Findings A cohort study of 1024 patients conducted at an urban academic medical center found that 13% of oral anticancer drug prescriptions were never received by the patient. The most common reason was because of patient and clinician decision-making; 13% of cases of failure to receive an oral anticancer drug prescription were directly associated with financial access issues. Meaning This study suggests that the failure to receive oral anticancer drugs is infrequent and that the reasons are multifactorial.

[1]  Laura A. Levit,et al.  Call to Action for Improving Oral Anticancer Agent Adherence. , 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  Pengxiang Li,et al.  Association of Patient Out-of-Pocket Costs With Prescription Abandonment and Delay in Fills of Novel Oral Anticancer Agents. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  A. Shields,et al.  Patient-reported preferences for oral versus intravenous administration for the treatment of cancer: a review of the literature , 2016, Patient preference and adherence.

[4]  A. Neugut,et al.  Non-initiation of adjuvant hormonal therapy in women with hormone receptor-positive breast cancer: The Breast Cancer Quality of Care Study (BQUAL) , 2012, Breast Cancer Research and Treatment.

[5]  J. Griggs,et al.  Patterns and correlates of adjuvant breast cancer endocrine therapy use. , 2011, Journal of Clinical Oncology.

[6]  V. Quinn,et al.  When to intervene to increase use of adjuvant hormone therapy among women with hormone-sensitive breast cancer. , 2011, Journal of Clinical Oncology.

[7]  L. Schwartzberg,et al.  Patient and plan characteristics affecting abandonment of oral oncolytic prescriptions. , 2011, Journal of oncology practice.

[8]  F. Camacho,et al.  Adjuvant hormonal therapy use among insured, low-income women with breast cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  C. Vanchieri When will the U.S. flinch at cancer drug prices? , 2005, Journal of the National Cancer Institute.

[10]  Aliza K Fink,et al.  Patient beliefs and tamoxifen discontinuance in older women with estrogen receptor--positive breast cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  E. Winer,et al.  Adherence to therapy with oral antineoplastic agents. , 2002, Journal of the National Cancer Institute.